<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088970</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0004</org_study_id>
    <nct_id>NCT02088970</nct_id>
  </id_info>
  <brief_title>Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)</brief_title>
  <acronym>CXL</acronym>
  <official_title>Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The corneal collagen cross linking is currently used in the treatment of keratoconus but this
      procedure has also a sterilizing non-specific effect on bacteria and fungus. So the corneal
      cross linking in association with the antibiotic treatment could result in a reduction of the
      duration of epithelial complete healing of the cornea.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties in reaching the desired number of patients and intermediate analysis leading to
    discontinuation of the study.
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of corneal complete epithelial healing in days.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size of the corneal scar</measure>
    <time_frame>3months</time_frame>
    <description>Size of the corneal scar at 3months expressed in % of the initial size of the corneal ulcer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thinning</measure>
    <time_frame>3 months</time_frame>
    <description>Corneal thinning estimated by Anterior segment optical coherence tomography at 3 months, expressed in microns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain of visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Gain of visual acuity, corresponding to the difference between the initial visual acuity and the 3months one. The visual acuity is measured with monoyer scale and converted in log Mar.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Bacterial Keratitis</condition>
  <condition>Fungal Keratitis</condition>
  <arm_group>
    <arm_group_label>antibiotic treatment alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crosslinking + Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crosslinking</intervention_name>
    <description>The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.</description>
    <arm_group_label>Crosslinking + Antibiotic</arm_group_label>
    <other_name>Riboflavine 0,1%.</other_name>
    <other_name>Ricrolin.</other_name>
    <other_name>CE 0037.</other_name>
    <other_name>médical device class IIb.</other_name>
    <other_name>Manufacter : SOOFT Distributor : Horus pharma.</other_name>
    <other_name>transmitter UV-A :</other_name>
    <other_name>Model : Vega, CBM X Linker. (CSO, Florence, Italie)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotic treatment</intervention_name>
    <description>If not the contact lens wearer -&gt; Cocci Gram positive cocci
Vancomycin + Fortum
If contact lens wearer -&gt; Gram negative bacillus
Fortum + Amiklin
If corticosteroids, immunosuppression, latent evolution -&gt; Fungus.
= Fortum + vancomycin + Fungizone</description>
    <arm_group_label>antibiotic treatment alone</arm_group_label>
    <arm_group_label>Crosslinking + Antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infectious bacterial or fungal keratitis with : size &gt; 2mm or within the central
             corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.

          -  Being major responsible.

          -  Agreement in writing to participate in the study.

          -  Being affiliated to a national insurance scheme.

        Exclusion Criteria:

          -  Present an infectious keratitis without all the previous criteria.

          -  Herpes or acanthamoeba keratitis

          -  preperforated or perforated cornea.

        General criteria:

          -  Pregnant woman.

          -  Minors(miners).

          -  Adults under guardianship.

          -  Patient can not be followed during 3 necessary months.

          -  French speaking patient.

          -  Unaffiliated patient in a national insurance scheme.

          -  HIV infected patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orignac</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious keratitis</keyword>
  <keyword>Corneal cross linking</keyword>
  <keyword>Topical antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

